<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32305093</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1474-547X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>395</Volume>
            <Issue>10232</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Lancet (London, England)</Title>
          <ISOAbbreviation>Lancet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.</ArticleTitle>
        <Pagination>
          <StartPage>1278</StartPage>
          <EndPage>1291</EndPage>
          <MedlinePgn>1278-1291</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(20)30262-2</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0140-6736(20)30262-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients with treatment-naive chronic lymphocytic leukaemia.</AbstractText>
          <AbstractText Label="METHODS">ELEVATE TN is a global, phase 3, multicentre, open-label study in patients with treatment-naive chronic lymphocytic leukaemia done at 142 academic and community hospitals in 18 countries. Eligible patients had untreated chronic lymphocytic leukaemia and were aged 65 years or older, or older than 18 years and younger than 65 years with creatinine clearance of 30-69 mL/min (calculated by use of the Cockcroft-Gault equation) or Cumulative Illness Rating Scale for Geriatrics score greater than 6. Additional criteria included an Eastern Cooperative Oncology Group performance status score of 2 or less and adequate haematologic, hepatic, and renal function. Patients with significant cardiovascular disease were excluded, and concomitant treatment with warfarin or equivalent vitamin K antagonists was prohibited. Patients were randomly assigned (1:1:1) centrally via an interactive voice or web response system to receive acalabrutinib and obinutuzumab, acalabrutinib monotherapy, or obinutuzumab and oral chlorambucil. Treatments were administered in 28-day cycles. To reduce infusion-related reactions, acalabrutinib was administered for one cycle before obinutuzumab administration. Oral acalabrutinib was administered (100 mg) twice a day until progressive disease or unacceptable toxic effects occurred. In the acalabrutinib-obinutuzumab group, intravenous obinutuzumab was given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 2 and on day 1 (1000 mg) of cycles 3-7. In the obinutuzumab-chlorambucil group, intravenous obinutuzumab was given on days 1 (100 mg), 2 (900 mg), 8 (1000 mg), and 15 (1000 mg) of cycle 1 and on day 1 (1000 mg) of cycles 2-6. Oral chlorambucil was given (0·5 mg/kg) on days 1 and 15 of each cycle, for six cycles. The primary endpoint was progression-free survival between the two combination-therapy groups, assessed by independent review committee. Crossover to acalabrutinib was allowed in patients who progressed on obinutuzumab-chlorambucil. Safety was assessed in all patients who received at least one dose of treatment. Enrolment for this trial is complete, and the study is registered at ClinicalTrials.gov, NCT02475681.</AbstractText>
          <AbstractText Label="FINDINGS">Between Sept 14, 2015, and Feb 8, 2017, we recruited 675 patients for assessment. 140 patients did not meet eligibility criteria, and 535 patients were randomly assigned to treatment. 179 patients were assigned to receive acalabrutinib-obinutuzumab, 179 patients were assigned to receive acalabrutinib monotherapy, and 177 patients were assigned to receive obinutuzumab-chlorambucil. At median follow-up of 28·3 months (IQR 25·6-33·1), median progression-free survival was longer with acalabrutinib-obinutuzumab and acalabrutinib monotherapy, compared with obinutuzumab-chlorambucil (median not reached with acalabrutinib and obinutuzumab vs 22·6 months with obinutuzumab, hazard ratio [HR] 0·1; 95% CI 0·06-0·17, p&lt;0·0001; and not reached with acalabrutinib monotherapy vs 22·6 months with obinutuzumab, 0·20; 0·13-0·3, p&lt;0·0001). Estimated progression-free survival at 24 months was 93% with acalabrutinib-obinutuzumab (95% CI 87-96%), 87% with acalabrutinib monotherapy (81-92%), and 47% with obinutuzumab-chlorambucil (39-55%). The most common grade 3 or higher adverse event across groups was neutropenia (53 [30%] of 178 patients in the acalabrutinib-obinutuzumab group, 17 [9%] of 179 patients in the acalabrutinib group, and 70 [41%] of 169 patients in the obinutuzumab-chlorambucil group). All-grade infusion reactions were less frequent with acalabrutinib-obinutuzumab (24 [13%] of 178 patients) than obinutuzumab-chlorambucil (67 [40%] of 169 patients). Grade 3 or higher infections occurred in 37 (21%) patients given acalabrutinib-obinutuzumab, 25 (14%) patients given acalabrutinib monotherapy, and 14 (8%) patients given obinutuzumab-chlorambucil. Deaths occurred in eight (4%) patients given acalabrutinib-obinutuzumab, 12 (7%) patients given acalabrutinib, and 15 (9%) patients given obinutuzumab-chlorambucil.</AbstractText>
          <AbstractText Label="INTERPRETATION">Acalabrutinib with or without obinutuzumab significantly improved progression-free survival over obinutuzumab-chlorambucil chemoimmunotherapy, providing a chemotherapy-free treatment option with an acceptable side-effect profile that was consistent with previous studies. These data support the use of acalabrutinib in combination with obinutuzumab or alone as a new treatment option for patients with treatment-naive symptomatic chronic lymphocytic leukaemia.</AbstractText>
          <AbstractText Label="FUNDING">Acerta Pharma, a member of the AstraZeneca Group, and R35 CA198183 (to JCB).</AbstractText>
          <CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sharman</LastName>
            <ForeName>Jeff P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Willamette Valley Cancer Institute/US Oncology, Eugene, OR, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Egyed</LastName>
            <ForeName>Miklos</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jurczak</LastName>
            <ForeName>Wojciech</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skarbnik</LastName>
            <ForeName>Alan</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; Lymphoproliferative Disorders Program, Novant Health Cancer Institute, Charlotte NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pagel</LastName>
            <ForeName>John M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flinn</LastName>
            <ForeName>Ian W</ForeName>
            <Initials>IW</Initials>
            <AffiliationInfo>
              <Affiliation>Sarah Cannon Research Institute, Tennessee Oncology Nashville, Nashville, TN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamdar</LastName>
            <ForeName>Manali</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Munir</LastName>
            <ForeName>Talha</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Haematological Malignancy Diagnostic Service (HMDS), St James's Institute of Oncology, Leeds, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walewska</LastName>
            <ForeName>Renata</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corbett</LastName>
            <ForeName>Gillian</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Tauranga Hospital, Tauranga, New Zealand.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fogliatto</LastName>
            <ForeName>Laura Maria</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herishanu</LastName>
            <ForeName>Yair</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Banerji</LastName>
            <ForeName>Versha</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Internal Medicine, Biochemistry &amp; Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coutre</LastName>
            <ForeName>Steven</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Stanford University School of Medicine, Stanford, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Follows</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Haematology, Addenbrooke's Hospital NHS Trust, Cambridge, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walker</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Peninsula Health, and Peninsula Private Hospital, Frankston, Victoria, Australia; Alfred Health, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karlsson</LastName>
            <ForeName>Karin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Haematology, Oncology and Radiophysics, Skåne University Hospital, Lund, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghia</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Janssens</LastName>
            <ForeName>Ann</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Department, University Hospitals Leuven, Leuven, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cymbalista</LastName>
            <ForeName>Florence</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Bobigny: Hématologie, CHU Avicennes, Bobigny, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Woyach</LastName>
            <ForeName>Jennifer A</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salles</LastName>
            <ForeName>Gilles</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie Clinique, Pierre-Bénite, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wierda</LastName>
            <ForeName>William G</ForeName>
            <Initials>WG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Munugalavadla</LastName>
            <ForeName>Veerendra</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Min Hui</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Sofia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Byrd</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, OH, USA. Electronic address: john.byrd@osumc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02475681</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R35 CA197734</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 CA198183</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Lancet</MedlineTA>
        <NlmUniqueID>2985213R</NlmUniqueID>
        <ISSNLinking>0140-6736</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>18D0SL7309</RegistryNumber>
          <NameOfSubstance UI="D002699">Chlorambucil</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D000077329">Agammaglobulinaemia Tyrosine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O43472U9X8</RegistryNumber>
          <NameOfSubstance UI="C543332">obinutuzumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Lancet. 2020 Apr 18;395(10232):1234-1236</RefSource>
          <PMID Version="1">32305083</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Nat Rev Clin Oncol. 2020 Jul;17(7):390</RefSource>
          <PMID Version="1">32358576</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Lancet. 2020 May 30;395(10238):1694</RefSource>
          <PMID Version="1">32473678</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077329" MajorTopicYN="N">Agammaglobulinaemia Tyrosine Kinase</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002699" MajorTopicYN="N">Chlorambucil</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32305093</ArticleId>
        <ArticleId IdType="mid">NIHMS1704385</ArticleId>
        <ArticleId IdType="pmc">PMC8151619</ArticleId>
        <ArticleId IdType="doi">10.1016/S0140-6736(20)30262-2</ArticleId>
        <ArticleId IdType="pii">S0140-6736(20)30262-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Eichhorst B, Fink AM, Bahlo J, et al.
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol
2016; 17: 928–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27216274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer K, Al-Sawaf O, Bahlo J, et al.
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med
2019; 380: 2225–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31166681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer K, Bahlo J, Fink AM, et al.
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood
2016; 127: 208–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26486789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Fischer K, Fingerle-Rowson G, et al.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet
2010; 376: 1164–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20888994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goede V, Fischer K, Busch R, et al.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med
2014; 370: 1101–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24401022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Ruppert AS, Heerema NA, et al.
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med
2018; 379: 2517–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6325637</ArticleId>
            <ArticleId IdType="pubmed">30501481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanafelt TD, Wang XV, Kay NE, et al.
Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med
2019; 381: 432–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6908306</ArticleId>
            <ArticleId IdType="pubmed">31365801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno C, Greil R, Demirkan F, et al.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol
2019; 20: 43–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30522969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tedeschi A, Barr PM, et al.
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med
2015; 373: 2425–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Sivina M, Jain N, et al.
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood
2019; 133: 1011–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6405333</ArticleId>
            <ArticleId IdType="pubmed">30530801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rafiq S, Butchar JP, Cheney C, et al.
Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol
2013; 190: 2702–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3631574</ArticleId>
            <ArticleId IdType="pubmed">23418626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golay J, Ubiali G, Introna M. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. Haematologica
2017; 102: e400–03.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5622871</ArticleId>
            <ArticleId IdType="pubmed">28642301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia. [news release]. Food and Drug Administration: November
21, 2019. https://www.fda.gov/news-events/press-announcements/fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-patients (accessed
Dec 10, 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Hassenruck F, Knodgen E, Gockeritz E, et al.
Sensitive detection of the natural killer cell-mediated cytotoxicity of anti-CD20 antibodies and its impairment by B-cell receptor pathway inhibitors. Biomed Res Int
2018; 2018: 1023490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5884282</ArticleId>
            <ArticleId IdType="pubmed">29750146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Woyach JA, Furman RR, et al.
Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1/2 ACE-CL-001 study. Blood
2018; 132 (suppl 1): 692.</Citation>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Rogers KA, Bhat SA, et al.
Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): three-year follow-up. J Clinical Oncol
2019; 37 (suppl 15): 7500.</Citation>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, et al.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood
2008; 111: 5446–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller MD, Paradis CF, Houck PR, et al.
Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res
1992; 41: 237–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1594710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaglowski SM, Jones JA, Nagar V, et al.
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood
2015; 126: 842–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4536539</ArticleId>
            <ArticleId IdType="pubmed">26116658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malcikova J, Tausch E, Rossi D, et al.
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia
2018; 32: 1070–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5940638</ArticleId>
            <ArticleId IdType="pubmed">29467486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalez D, Martinez P, Wade R, et al.
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol
2011; 29: 2223–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21483000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rawstron AC, Bottcher S, Letestu R, et al.
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia
2013; 27: 142–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23041722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheson BD, Byrd JC, Rai KR, et al.
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol
2012; 30: 2820–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3410400</ArticleId>
            <ArticleId IdType="pubmed">22778323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol
2016; 17: 779–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27185642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Nabhan C, Thompson MC, et al.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica
2018; 103: 874–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5927982</ArticleId>
            <ArticleId IdType="pubmed">29419429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Roeker LE, Allan JN, et al.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol
2018; 93: 1394–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7552812</ArticleId>
            <ArticleId IdType="pubmed">30132965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol
2019; 94: 1266–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31364186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kipps TJ, Fraser G, Coutre SE, et al.
Long-term studies assessing outcomes of ibrutinib therapy in patients with del(11q) chronic lymphocytic leukemia. Clin Lymphoma, Myeloma Leuk
2019; 19: 715–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31447270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh SA, Rabe KG, Call TG, et al.
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol
2013; 162: 774–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4098845</ArticleId>
            <ArticleId IdType="pubmed">23841899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi D, Cerri M, Capello D, et al.
Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol
2008; 142: 202–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18492108</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
